The results indicated that pancreatic β-cell function and stimulation levels were retained at 12 months in the FMT group, suggesting that FMT can protect pancreatic β-cell function in patients with diabetes diagnosed 12 months after onset and avoid a drop in endogenous insulin production. This evidence concerns the gene INS and diabetes mellitus.